Search results
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Zacks via Yahoo Singapore Finance· 1 week agoMerck MRK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
US FDA approves Merck's therapy for rare lung condition
Reuters via Yahoo Singapore Finance· 3 months agoThe U.S. Food and Drug Administration on Tuesday approved Merck's treatment for adults with high...
Bristol Myers (BMY) Gets FDA Nod for Reblozyl Label Expansion
Zacks via Yahoo Singapore Finance· 10 months agoBristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of...
Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl
Zacks via Yahoo Singapore Finance· 1 year agoBristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for...
FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease
Zacks via Yahoo Singapore Finance· 9 months agoThe FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with...
Merck (MRK) Posts Positive Results From PAH Drug Study
Zacks via Yahoo Singapore Finance· 2 years agoMerck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary...
Bull of the Day: Merck & Co. (MRK)
Zacks via Yahoo News· 2 years agoMerck & Co. (MRK) is a $240 billion market cap pharmaceutical titan that's climbed over 20% in 2022. The firm is continuing to make acquisitions and many...
bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth
Zacks via Yahoo News· 2 years agobluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is...
Merck to buy Imago for $1.35 billion to broaden portfolio of blood disorder drugs
Reuters via Yahoo Singapore Finance· 2 years ago(Reuters) -Merck & Co Inc said on Monday it will acquire cancer drug developer Imago BioSciences Inc...
Merck upgrades guidance on stronger 2023 outlook as COVID business declines
Yahoo Finance· 11 months agoMerck (MRK) reported earnings and upgraded its 2023 guidance Tuesday, as demand slows for COVID...
